Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008–2009)

Armstrong-James, 2007, Invasive Candida species infection: the importance of adequate empirical antifungal therapy, J Antimicrob Chemother, 60, 459, 10.1093/jac/dkm260 Corona, 2008, Timely selection of adequate antifungal therapy for candidemia in the critically ill: don’t let the yeast rise!, Crit Care Med, 36, 3097, 10.1097/CCM.0b013e31818b9375 Morgan, 2005, Global trends in candidemia: review of reports from 1995–2005, Curr Infect Dis Rep, 7, 429, 10.1007/s11908-005-0044-7 Parkins, 2007, Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections, J Antimicrob Chemother, 60, 613, 10.1093/jac/dkm212 Pfaller, 2001, J Clin Microbiol, 39, 3254, 10.1128/JCM.39.9.3254-3259.2001 Pfaller, 2006, Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints, J Clin Microbiol, 44, 819, 10.1128/JCM.44.3.819-826.2006 Arnold, 2010, Hospital resource utilization and costs of inappropriate treatment of candidemia, Pharmacotherapy, 30, 361, 10.1592/phco.30.4.361 Garey, 2006, Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study, Clin Infect Dis, 43, 25, 10.1086/504810 Garey, 2007, Economic analysis of inadequate fluconazole therapy in non-neutropenic patients with candidaemia: a multi-institutional study, Int J Antimicrob Agents, 29, 557, 10.1016/j.ijantimicag.2007.01.001 Hsu, 2010, A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients, J Antimicrob Chemother, 65, 1765, 10.1093/jac/dkq216 Labelle, 2008, Treatment-related risk factors for hospital mortality in Candida bloodstream infections, Crit Care Med, 36, 2967, 10.1097/CCM.0b013e31818b3477 Morrell, 2005, Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality, Antimicrob Agents Chemother, 49, 3640, 10.1128/AAC.49.9.3640-3645.2005 Zilberberg, 2010, Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study, BMC Infect Dis, 10, 150, 10.1186/1471-2334-10-150 Almirante, 2005, Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003, J Clin Microbiol, 43, 1829, 10.1128/JCM.43.4.1829-1835.2005 Bassetti, 2006, Epidemiological trends in nosocomial candidemia in intensive care, BMC Infect Dis, 6, 21, 10.1186/1471-2334-6-21 Eggimann, 2003, Epidemiology of Candida species infections in critically ill non-immunosuppressed patients, Lancet Infect Dis, 3, 685, 10.1016/S1473-3099(03)00801-6 Leone, 2003, Long-term epidemiological survey of Candida species: comparison of isolates found in an intensive care unit and in conventional wards, J Hosp Infect, 55, 169, 10.1016/j.jhin.2003.07.003 Leroy, 2009, Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005–2006), Crit Care Med, 37, 1612, 10.1097/CCM.0b013e31819efac0 Lipsett, 2006, Surgical critical care: fungal infections in surgical patients, Crit Care Med, 34, S215, 10.1097/01.CCM.0000231883.93001.E0 Mean, 2008, Bench-to-bedside review: Candida infections in the intensive care unit, Crit Care, 12, 204, 10.1186/cc6212 Playford, 2010, Increasing incidence of candidaemia: long-term epidemiological trends, Queensland, Australia, 1999–2008, J Hosp Infect, 76, 46, 10.1016/j.jhin.2010.01.022 Xie, 2008, Impact of invasive fungal infection on outcomes of severe sepsis: a multicenter matched cohort study in critically ill surgical patients, Crit Care, 12, R5, 10.1186/cc6766 Zilberberg, 2009, Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation, Crit Care, 13, R94, 10.1186/cc7924 Zilberberg, 2009, Fungal infections in the ICU, Infect Dis Clin North Am, 23, 625, 10.1016/j.idc.2009.04.008 Pfaller, 2002, Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility, J Clin Microbiol, 40, 3551, 10.1128/JCM.40.10.3551-3557.2002 Dimopoulos, 2009, A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece, Antimicrob Agents Chemother, 53, 1242, 10.1128/AAC.01368-08 Fridkin, 2001, Increasing prevalence of antimicrobial resistance in intensive care units, Crit Care Med, 29, N64, 10.1097/00003246-200104001-00002 Fridkin, 1999, Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals, Clin Infect Dis, 29, 245, 10.1086/520193 Martin, 2003, The epidemiology of sepsis in the United States from 1979 through 2000, N Engl J Med, 348, 1546, 10.1056/NEJMoa022139 Wisplinghoff, 2004, Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study, Clin Infect Dis, 39, 309, 10.1086/421946 Pfaller, 2010, Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods, Drug Resist Updat, 13, 180, 10.1016/j.drup.2010.09.002 Pfaller, 2011, Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria, Drug Resist Updat, 10.1016/j.drup.2011.01.004 Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. 3rd ed. Document M27-A3. Wayne, PA: CLSI; 2008. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; third informational supplement. Document M27-S3. Wayne, PA: CLSI; 2008. Pfaller, 2011, Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009), J Clin Microbiol, 49, 396, 10.1128/JCM.01398-10 Pfaller, 2008, Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program, J Clin Microbiol, 46, 551, 10.1128/JCM.01952-07 Trick, 2002, Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989–1999, Clin Infect Dis, 35, 627, 10.1086/342300 Fridkin, 2006, Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995–2004, Pediatrics, 117, 1680, 10.1542/peds.2005-1996 Hajjeh, 2004, Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program, J Clin Microbiol, 42, 1519, 10.1128/JCM.42.4.1519-1527.2004 Kollef, 2008, Health care-associated infection (HAI): a critical appraisal of the emerging threat—Proceedings of the HAI Summit, Clin Infect Dis, 47, S55, 10.1086/590937 Sofair, 2006, Epidemiology of community-onset candidemia in Connecticut and Maryland, Clin Infect Dis, 43, 32, 10.1086/504807 Sobel, 2008, Changing epidemiology of invasive candidiasis in intensive care units—much ado about nothing?, Crit Care Med, 36, 2188, 10.1097/CCM.0b013e318170fa45 Sobel, 2010, Changing trends in the epidemiology of Candida blood stream infections: a matter for concern?, Crit Care Med, 38, 990, 10.1097/CCM.0b013e3181d16866 Chandwani, 2009, Utilization and dosage pattern of echinocandins for treatment of fungal infections in US hospital practice, Curr Med Res Opin, 25, 385, 10.1185/03007990802619599 Cohen, 2010, Early prediction of Candida glabrata fungemia in nonneutropenic critically ill patients, Crit Care Med, 38, 826, 10.1097/CCM.0b013e3181cc4734 Oxman, 2010, Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern?, J Antimicrob Chemother, 65, 1460, 10.1093/jac/dkq136 Sun, 2010, Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review, Int J Antimicrob Agents, 35, 211, 10.1016/j.ijantimicag.2009.09.020 Pfeiffer, 2010, Breakthrough invasive candidiasis on micafungin, J Clin Microbiol, 48, 2373, 10.1128/JCM.02390-09 Chapeland-Leclerc, 2010, Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient, Antimicrob Agents Chemother, 54, 1360, 10.1128/AAC.01138-09 Pappas, 2009, Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America, Clin Infect Dis, 48, 503, 10.1086/596757 Kabbara, 2008, Breakthrough C. parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy, Haematologica, 93, 639, 10.3324/haematol.11149 Sipsas, 2009, Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001–2007): stable incidence but changing epidemiology of a still frequently lethal infection, Cancer, 115, 4745, 10.1002/cncr.24507